UK Regulator ‘Optimistic’ About EU Proposals For Northern Ireland Drug Supply
MHRA Fields Tricky Post-Brexit Regulatory Questions
Among the many problems thrown up by Brexit is how to deal with situations where an innovative product that falls within the scope of the EU centralized procedure is filed in Great Britain but not in the EU, potentially denying access to the medicine in Northern Ireland. A recent webinar saw officials from the UK regulator explain the new rules on medicines supply between GB and NI.
You may also be interested in...
The UK regulator explains the new requirements for batch testing and release in Great Britain and Northern Ireland, what's involved in importing clinical trial drugs to Northern Ireland, and what factors determine the location of the Qualified Person.
The latest proposals for solving regulatory and trade issues caused by Brexit and the Northern Ireland Protocol have been welcomed by EU and UK pharmaceutical industry bodies.
A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time.